Literature DB >> 19707241

Immunotherapy: Can we include vaccines with stem-cell transplantation?

John Barrett1, Katayoun Rezvani.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19707241     DOI： 10.1038/nrclinonc.2009.115

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.

Authors:  Rena J May; Tao Dao; Javier Pinilla-Ibarz; Tatyana Korontsvit; Victoriya Zakhaleva; Rong H Zhang; Peter Maslak; David A Scheinberg
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

2.  Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.

Authors:  M Bocchia; S Gentili; E Abruzzese; A Fanelli; F Iuliano; A Tabilio; M Amabile; F Forconi; A Gozzetti; D Raspadori; S Amadori; F Lauria
Journal:  Lancet       Date:  2005 Feb 19-25       Impact factor: 79.321

Review 3.  Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.

Authors:  Katayoun Rezvani; A John Barrett
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

4.  Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia.

Authors:  Zihai Li; Yi Qiao; Bei Liu; Elizabeth J Laska; Priyamvadha Chakravarthi; Judith M Kulko; Robert D Bona; Min Fang; Upendra Hegde; Victor Moyo; Susan H Tannenbaum; Antoine Ménoret; Judy Gaffney; Laura Glynn; Carolyn D Runowicz; Pramod K Srivastava
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

5.  Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

Authors:  Katayoun Rezvani; Agnes S M Yong; Stephan Mielke; Bipin N Savani; Laura Musse; Jeanine Superata; Behnam Jafarpour; Carol Boss; A John Barrett
Journal:  Blood       Date:  2007-09-17       Impact factor: 22.113

6.  Donor-recipient polymorphism of the proteinase 3 gene: a potential target for T-cell alloresponses to myeloid leukemia.

Authors:  E Clave; J Molldrem; N Hensel; A Raptis; A J Barrett
Journal:  J Immunother       Date:  1999-01       Impact factor: 4.456

7.  Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.

Authors:  Yoshihiro Oka; Akihiro Tsuboi; Tetsuya Taguchi; Tadashi Osaki; Taiichi Kyo; Hiroko Nakajima; Olga A Elisseeva; Yusuke Oji; Manabu Kawakami; Kazuhiro Ikegame; Naoki Hosen; Satoshi Yoshihara; Fei Wu; Fumihiro Fujiki; Masaki Murakami; Tomoki Masuda; Sumiyuki Nishida; Toshiaki Shirakata; Shin-Ichi Nakatsuka; Ayako Sasaki; Keiko Udaka; Hiroo Dohy; Katsuyuki Aozasa; Shinzaburo Noguchi; Ichiro Kawase; Haruo Sugiyama
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-13       Impact factor: 11.205

8.  A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique.

Authors:  Stephan Mielke; Raquel Nunes; Katayoun Rezvani; Vicki S Fellowes; Annie Venne; Scott R Solomon; Yong Fan; Emma Gostick; David A Price; Christian Scotto; Elizabeth J Read; A John Barrett
Journal:  Blood       Date:  2007-09-18       Impact factor: 22.113

9.  Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.

Authors:  Katayoun Rezvani; Agnes S M Yong; Bipin N Savani; Stephan Mielke; Keyvan Keyvanfar; Emma Gostick; David A Price; Daniel C Douek; A John Barrett
Journal:  Blood       Date:  2007-05-15       Impact factor: 22.113
  9 in total
  6 in total

Review 1.  Immunotherapy prospects for acute myeloid leukaemia.

Authors:  A J Barrett; K Le Blanc
Journal:  Clin Exp Immunol       Date:  2010-05-31       Impact factor: 4.330

Review 2.  Minimal residual disease in acute myeloid leukaemia.

Authors:  Christopher S Hourigan; Judith E Karp
Journal:  Nat Rev Clin Oncol       Date:  2013-06-25       Impact factor: 66.675

Review 3.  Relapse after allogeneic stem cell transplantation.

Authors:  A John Barrett; Minoo Battiwalla
Journal:  Expert Rev Hematol       Date:  2010-08       Impact factor: 2.929

4.  Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.

Authors:  Alana A Kennedy-Nasser; Stephanie Ku; Paul Castillo-Caro; Yasmin Hazrat; Meng-Fen Wu; Hao Liu; Jos Melenhorst; A John Barrett; Sawa Ito; Aaron Foster; Barbara Savoldo; Eric Yvon; George Carrum; Carlos A Ramos; Robert A Krance; Kathryn Leung; Helen E Heslop; Malcolm K Brenner; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2014-02-26       Impact factor: 12.531

Review 5.  Cancer vaccines and T cell therapy.

Authors:  Katayoun Rezvani; Joshua D Brody; Holbrook E Kohrt; Aaron C Logan; Ranjana Advani; Debra Katherine Czerwinski; Wen-Kai Weng; Robert S Negrin; Victoria Carlton; Malek Faham; Ronald Levy; John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-03       Impact factor: 5.742

Review 6.  Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic).

Authors:  Kazusa Ishii; Austin J Barrett
Journal:  Ther Adv Hematol       Date:  2016-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.